The University of Chicago Header Logo

Connection

Mitchell C. Posner to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Mitchell C. Posner has written about Drug Resistance, Neoplasm.
Mitchell C. Posner
Connection Strength
0.192
Drug Resistance, Neoplasm
  1. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.
    View in: PubMed
    Score: 0.122
  2. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66.
    View in: PubMed
    Score: 0.058
  3. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.